NClip

Substance Use Disorders

15 min read

Substance Use Disorders

Key Points

  • Substance use disorders involve repeated use of alcohol or drugs that impairs health and role function at home, work, or school.
  • Neuroadaptation in the basal-ganglia, extended-amygdala, and prefrontal-cortex drives tolerance, withdrawal, and compulsive use.
  • Clinical progression often moves from intoxication and misuse to dependence, addiction, and overdose risk.
  • Nursing priorities include withdrawal screening, safety planning, stigma-free communication, and linkage to ongoing treatment.
  • Adult safety impact is broad across socioeconomic groups and extends to family-system harm when misuse is untreated.
  • In pregnancy, universal validated screening and SBIRT-based follow-up are key to reducing maternal-fetal harm.
  • Unintentional overdose is a major adult injury/death pathway, and polysubstance combinations sharply increase lethality.
  • Terminology choices influence bias: person-first language and “misuse” framing can improve therapeutic alliance compared with blame-associated labels.
  • U.S. burden remains high, including CDC-reported estimates that about 1 in 7 Americans experience SUD and about 1.6 million people live with OUD.
  • In youth populations, alcohol remains the most commonly used substance, and concurrent exposure to vaping and cannabis is common in high-school cohorts.
  • In AFAB populations, alcohol and drug effects may be amplified at similar intake, and stigma barriers (including caregiving/custody fears) can delay treatment engagement.
  • National disparity data show low completion rates for SUD treatment (under half overall), with the lowest completion in non-Hispanic Native Hawaiian/Pacific Islander populations.
  • Opioid-overdose mortality increases have been especially severe in non-Hispanic Black populations in large urban settings, requiring equity-focused response pathways.
  • Population-level overdose response is strongest when harm-reduction access (naloxone and syringe services), PDMP-informed prescribing controls, and cross-sector community partnerships are implemented together.

Pathophysiology

Substance use disorders are chronic brain-based disorders involving reward, stress, and executive-control systems. Repeated substance exposure increases dopamine-driven reinforcement in the reward pathway, then produces neuroadaptation that blunts normal reward response. As tolerance develops, larger or more frequent doses are required for similar effect.

When use decreases, withdrawal symptoms emerge and are often relieved only by further use, reinforcing compulsive patterns. Clinical progression often shifts from impulsive experimentation and positive reinforcement (“using to feel good”) to compulsive use and negative reinforcement (“using to avoid feeling bad”). This cycle contributes to neglect of relationships, work, and self-care, while raising risk of medical and psychiatric complications.

Neuroadaptation in the basal-ganglia, extended-amygdala, and prefrontal-cortex helps explain recurrent binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation patterns seen across SUD presentations.

In the binge/intoxication stage, reward signaling in the nucleus accumbens is reinforced through dopamine and opioid pathways. With repeated use, people can develop strong learned cue associations (for example people, places, paraphernalia, and internal mood states), so cue exposure alone can trigger craving and substance-seeking behavior even during recovery.

In the withdrawal/negative-affect stage, chronic exposure is associated with reduced dopamine-receptor activity and blunted dopamine response, which can decrease reward sensitivity to both substances and natural reinforcers. This can present clinically as anhedonia, reduced motivation for routine self-care, and compulsive dose escalation attempts to recapture prior reward effects. Extended-amygdala stress signaling (for example CRF, norepinephrine, and dynorphin pathways) also contributes to dysphoria and stress-triggered return-to-use patterns.

In the preoccupation/anticipation stage, prefrontal-cortex dysfunction weakens executive control (decision-making, behavioral inhibition, planning, and impulse regulation), increasing vulnerability to relapse when trigger or stress exposure occurs.

Classification

  • Misuse: Harmful pattern of use by amount, frequency, or context.
  • Habituation: Repetitive use pattern in which behavior becomes routine and difficult to stop even before full physiologic withdrawal syndromes dominate.
  • Dependence: Physiologic and psychological withdrawal when use stops.
  • Addiction: Compulsive, uncontrolled use with relapse risk despite consequences.
  • DSM-5-TR SUD diagnosis: Two or more criteria within a 12-month period (for example, craving, role failure, hazardous use, tolerance, withdrawal, and unsuccessful cut-down attempts).
  • Severity by criteria count: Mild (2-3), moderate (4-5), and severe (6 or more).
  • Remission specifier: Early remission means no criteria for at least 3 months; sustained remission means no criteria for at least 12 months.
  • Three-stage addiction cycle: Binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation.
  • Relapse-burden context: Relapse is common after treatment (often more than half within the first year after discharge) and does not by itself indicate treatment failure.
  • Common substances and behaviors: Alcohol, cannabis, opioids, stimulants, and selected nonsubstance behaviors; in DSM-5-TR, gambling disorder is the primary nonsubstance disorder with formal diagnostic criteria.
  • Gambling-disorder diagnostic context: Persistent/recurrent problematic gambling with clinically significant distress or impairment, typically requiring 4 or more DSM criteria within 12 months and exclusion of manic-episode explanation.
  • Substance-category domain: Alcohol; illicit drugs (including nonmedical prescription use); nonmedical over-the-counter agents (for example dextromethorphan and pseudoephedrine products); and other inhalants or Delta-8 THC products.
  • Controlled-substance schedule domain: DEA Schedules I-V classify drugs by accepted medical use plus abuse/dependence potential (Schedule I highest restriction, Schedule V lowest).
  • Genetic-risk context: Inherited vulnerability contributes substantially to addiction risk (often estimated around 40-70%) and interacts with environmental exposure.
  • Prevention-tier model: Universal interventions target the whole population, selective interventions target high-risk subgroups, and indicated interventions target people already misusing substances who do not yet meet SUD criteria.
  • Treatment-disparity domain: Completion and access patterns vary by population group, so retention and follow-up planning should include equity-specific barriers.

Nursing Assessment

NCLEX Focus

Differentiate intoxication, withdrawal, and overdose first; immediate priorities are airway, breathing, circulation, and safety.

  • Assess substance type, route, amount, frequency, and last use.
  • In poisoning-compatible presentations, assess exposure pathway (ingestion, inhalation, or dermal absorption) and likely household/occupational chemical contributors.
  • Perform focused mental-status assessment for SUD presentations (distress signs, level of consciousness/orientation changes, appearance/behavior, speech/motor pattern, mood/affect shifts, thought/perception disturbance, and insight/judgment deficits).
  • In nonpsychiatric settings (for example primary care, obstetrics-gynecology, emergency, and medical-surgical units), screen actively because SUD is frequently underdiagnosed.
  • Clarify whether substances are controlled (DEA schedule) versus noncontrolled OTC/inhalant products because risk profile and legal handling differ.
  • Review prescription-drug-monitoring-program (PDMP) data per policy/order when controlled-substance misuse, diversion, or multisource prescribing is suspected.
  • Assess DSM-5-TR criteria count within the past 12 months and current severity impact on daily function.
  • Use age-appropriate screeners (for example ASSIST and CRAFFT for adolescents) when pediatric or teen substance-use risk is suspected.
  • In adolescent assessment, include recent prevalence anchors (for example alcohol use in many 12th-grade cohorts and common illicit-drug exposure opportunity) to normalize direct screening questions.
  • Assess withdrawal symptoms and trend severity with tools such as CIWA-Ar, COWS, or CINA when indicated.
  • Distinguish dependence (withdrawal with dose reduction/cessation) from tolerance (need for increasing dose to achieve prior effect), because management and teaching differ.
  • For suspected opioid-withdrawal states, assess common symptom clusters (for example sweating, confusion, enlarged pupils, appetite loss, diarrhea/vomiting, cramps/tremor, yawning, and flu-like symptoms).
  • During withdrawal, assess for anhedonia, reduced interest in natural rewards, appetite/self-care decline, and stress-reactive craving because these can reinforce rapid return-to-use.
  • Assess co-occurring psychiatric symptoms, trauma history, suicidality, and social risk factors.
  • Use structured psychosocial interviewing (for example PQRSTU prompts) to clarify triggers, perceived benefits, physical effects, severity of life impact, timing/progression, and patient understanding of substance use.
  • Introduce suicide/NSSI screening as a standard safety step (for example PSS-3 style first-pass questions), explain the purpose to reduce perceived intrusiveness, and escalate immediately when positive.
  • Add culturally and spiritually responsive assessment when planning SUD care (for example CFI-style cultural meaning/support questions and FICA domains for spiritual coping/distress cues).
  • Assess cue-trigger map (people, places, paraphernalia, and internal mood states) to identify high-risk relapse contexts and guide prevention planning.
  • Assess executive-function impairment (decision-making, inhibition control, planning, and impulse regulation) when relapse risk remains high despite stated motivation to stop.
  • Assess bidirectional comorbidity risk because SUD and other mental-health disorders frequently co-occur and worsen outcomes when untreated together.
  • When dual-diagnosis patterns are present, consider three explanatory pathways: substances masking psychiatric symptoms, substances triggering psychiatric disorders, or shared biologic/trauma vulnerability driving both conditions.
  • Assess major risk domains: early initiation, genetic/family history, family conflict, peer exposure, substance availability, chronic stress, and ACE burden.
  • In adolescent/young-adult histories, treat early initiation as high risk (for example first use by age 17 or younger) and assess duration-intensity progression.
  • Assess persistent childhood-adolescent risk markers (emotional distress/aggressiveness, rebelliousness, favorable attitudes toward use, and peer-use normalization).
  • Assess school-function risk markers (early academic failure and low school commitment) because they correlate with later SUD progression.
  • Assess prevention-risk context: low parental supervision, high home/community conflict, and normalization pressures from media/advertising exposure.
  • Assess protective-factor profile across individual, family, school, and community systems (for example social-emotional-behavioral competence, self-efficacy, spirituality/resilience, positive social involvement, recognition for positive behavior, and clear no-use norms).
  • Assess emotional self-regulation problems because dysregulation can both precede and worsen SUD.
  • Assess prevention-tier fit by risk level (universal versus selective versus indicated) before selecting education-only versus structured referral pathways.
  • Assess intoxication cues by substance pattern, including cannabis cues (conjunctival erythema, increased appetite, dry mouth, tachycardia) and opioid cues (miosis with sedation and cognitive slowing).
  • In ED opioid/heroin presentations, assess for respiratory/CNS depression, shallow respirations, reduced responsiveness, and potential associated findings (for example urticaria, hypotension, seizure activity, or agitation).
  • For sedative-hypnotic-anxiolytic exposures, assess alcohol-like CNS-depression signs (slurred speech, ataxia, nystagmus, impaired cognition, stupor/coma) and monitor ventilation risk closely.
  • Do not assume a routine urine drug screen excludes benzodiazepine exposure; some agents require specific benzodiazepine metabolite testing.
  • Assess objective substance evidence using ordered blood, urine, or hair tests when clinical presentation and history are discordant.
  • Assess common withdrawal-pattern clusters by substance class to guide monitoring urgency (for example alcohol autonomic escalation/seizure risk, opioid GI-musculoskeletal distress, stimulant mood-crash depression, nicotine irritability and sleep disruption).
  • For alcohol withdrawal, assess progression severity from autonomic activation to severe delirium-tremens patterns (hallucinations, seizures, tachycardia, hypertension, and hyperthermia).
  • For adolescents, ask directly about non-prescribed pain-medicine use, hiding behavior from caregivers, and obtaining medications from nonmedical channels.
  • For older adults, adapt communication for sensory/cognitive limitations and assess polypharmacy interaction risk and slower drug metabolism.
  • In older adults, differentiate possible SUD presentations (falls, confusion, sleep disturbance, and social withdrawal) from dementia-only assumptions before finalizing the cause of decline.
  • For pregnant patients, assess exposure urgently because maternal choices directly affect fetal outcomes and neonatal withdrawal risk.
  • In pregnancy-specific workflows, use validated prenatal screening tools and classify positive screens for follow-up intervention.
  • Include baseline laboratory and diagnostic evaluation when indicated: CBC, glucose, electrolytes (including potassium, magnesium, phosphate), creatinine, liver enzymes, amylase/lipase, urine toxicology, blood alcohol level, urine hCG in reproductive-age patients, and ECG in older/high-risk adults.
  • Obtain prior withdrawal/treatment history in detail (settings used, medications tried, what was helpful/not helpful, and prior recovery-program engagement) to guide post-withdrawal planning.
  • Assess functional impact (employment, parenting, legal exposure, housing instability).
  • Assess overdose risk factors, including reduced tolerance after abstinence.
  • Assess polysubstance pattern risk (for example opioid plus benzodiazepine or alcohol, and stimulant plus opioid combinations) when overdose history or sedation episodes are present.
  • In long-term stimulant exposure (especially methamphetamine), assess for paranoia, hallucinations, and delusions that can mimic primary psychotic disorders and complicate diagnosis.
  • Use sex-informed risk interpretation: males show higher overall alcohol-use-disorder prevalence, while females may progress faster from first use to SUD for selected substances and can experience stronger withdrawal burden in some drug classes.
  • In AFAB-focused screening, assess for disproportionate functional impact at lower exposure (for example higher blood alcohol concentration at similar intake) and for barriers such as child-custody fears or gender-specific treatment-access gaps.
  • In culturally responsive alcohol-risk assessment, recognize that aldehyde-metabolism variants in some East Asian populations can cause flushing/nausea/tachycardia and may lower AUD prevalence while increasing cancer risk among those who continue heavy alcohol use.
  • For suspected gambling disorder, assess hallmark criteria such as tolerance-like escalating bets, failed cut-down attempts, preoccupation, distress-driven gambling, chasing losses, concealment/lying, and relationship or financial disruption.
  • In health care workforce contexts, differentiate stress from potential SUD impairment using combined behavioral, physical, and diversion-pattern cues before escalation through policy channels.

Nursing Interventions

  • Use nonjudgmental, therapeutic communication to reduce stigma and improve engagement.
  • Use motivational interviewing (OARS, empathy, discrepancy focus, autonomy support) to address ambivalence about abstinence and treatment adherence.
  • Match communication to readiness-for-change stage; explore rather than confront denial, avoid ultimatums/power struggles, reflect strengths, and keep boundaries clear and compassionate.
  • Prioritize early identification of problematic use patterns before severe withdrawal, overdose, or social destabilization occurs.
  • In school and adolescent counseling settings, emphasize that early alcohol/drug misuse raises later-life substance-use-disorder risk and warrants early intervention.
  • Coach caregivers to initiate early, developmentally appropriate conversations about alcohol/drug risks and prevention expectations (for example “Talk. They Hear You”-style parent guidance).
  • Use prevention-tier matching in care planning: universal education/policy reinforcement for broad populations, selective targeted referral for high-risk groups, and indicated skills-based programs for early misuse without established SUD.
  • Initiate symptom-triggered withdrawal care protocols and frequent reassessment.
  • Provide hydration, nutrition support, sleep support, and fall/seizure precautions as needed.
  • During withdrawal care, prioritize ABC stabilization first, then implement safety measures (for example fall precautions, seizure precautions, and ready suction/oxygen when severe alcohol withdrawal risk is present).
  • In high-risk ED withdrawal/intoxication care, apply protocolized severity scoring (for example CIWA-Ar for alcohol and COWS for opioids) and escalate treatment based on trend.
  • In sedative-hypnotic overdose risk, prioritize airway support and consider capnography to detect hypoventilation early.
  • For uncertain or mixed ingestions, consult poison-control services early (U.S. 1-800-222-1222) and use bedside toxicology support when available.
  • Use exposure-matched PPE for suspected toxic contamination and prevent secondary staff/family exposure during stabilization workflows.
  • Administer indicated reversal and withdrawal medications per protocol (for example naloxone for opioid overdose, benzodiazepines for alcohol withdrawal, and seizure-support medications when ordered) with close cardiopulmonary monitoring.
  • When toxicology guidance indicates, support elimination strategies such as urine alkalinization, hemodialysis, or continuous renal replacement therapy with ordered monitoring.
  • Coordinate referrals to detox, residential, outpatient, and peer-support services.
  • Prioritize disparity-focused retention strategy (rapid follow-up, transport/coverage support, and culturally responsive engagement) when treatment-completion risk is high.
  • Build individualized plans that account for social, financial, transportation, and family-environment barriers to sustained treatment engagement.
  • Include family/caregiver education and support linkage when appropriate because SUD burden commonly affects the full household system.
  • Teach families supportive, non-enabling involvement (emotional support, boundary-setting, and caregiver-stress management) to improve treatment continuity.
  • Teach relapse and overdose prevention, including emergency response resources.
  • Co-develop a client-centered post-withdrawal plan with the interprofessional team that includes readiness-for-change level, follow-up setting, and concrete next-step appointments before discharge.
  • Teach high-risk interaction avoidance for sedative combinations and counsel that opioid-contaminated supply can raise overdose risk even with intermittent use.
  • Teach that recovery is a long-term process, not detox completion alone; relapse can signal need for treatment-plan adjustment rather than failure.
  • Reinforce that recovery extends beyond abstinence alone and includes health, function, and self-directed life goals.
  • Use person-first language (for example, “person with SUD”) to reduce stigma barriers to disclosure and treatment engagement.
  • When possible, prefer “misuse” wording over blame-centered terms in direct patient communication to reduce shame and support engagement.
  • Avoid stigmatizing labels (for example abuser, addict, alcoholic, or medication seeker) and document using diagnosis-based language.
  • In professional-peer safety events, report suspected impairment promptly through supervisor/policy pathways and support early treatment linkage to reduce patient-harm risk.
  • In prenatal settings, apply SBIRT after positive screening and coordinate referral pathways that include mental-health/IPV co-assessment when indicated.
  • If toxicology testing is used in pregnancy, follow informed-consent and confirmatory-testing safeguards due false-positive and legal-reporting implications.
  • Teach and reinforce protective factors at multiple levels: self-efficacy, social-emotional-behavioral competence, spirituality/resilience, positive prosocial bonding, and clear no-use norms in family/school/community settings.
  • Reinforce universal prevention strategies by counseling on policy and family-program supports that reduce population risk (for example impaired-driving laws with 0.08 BAC limits, minimum-drinking-age enforcement, and family-focused prevention programs such as Strengthening Families Program).
  • In opioid-specific prevention counseling, reinforce that reducing unnecessary opioid prescribing lowers later OUD risk, and teach safe home storage/disposal to reduce diversion and accidental exposure.
  • Expand overdose-response access with naloxone distribution and linkage to evidence-based treatment pathways in populations with rising overdose mortality burden.
  • In community opioid-response planning, support mandated PDMP utilization to reduce multisource prescribing, diversion patterns, and opioid-related overdose burden.
  • Support syringe-service pathways with STI/HIV testing and counseling, and teach that these programs reduce infectious-disease transmission without increasing community drug-use rates.
  • For selective prevention, refer high-risk families and youth to structured programs when available (for example Nurse-Family Partnership, Familias Unidas, and BASICS-style brief motivational interventions for college populations).
  • For indicated prevention, link youth already misusing substances to skills-based interventions (for example Coping Power-type self-regulation/social-competence programs) and schedule active follow-up to prevent progression to SUD.

Post-Detox Overdose Risk

Tolerance drops after detox; return to prior dose can be fatal, especially with opioids.

Pharmacology

Pharmacologic management is substance-specific and often symptom-triggered during withdrawal. Core nursing responsibilities include protocol adherence, reassessment after each dose, adverse-effect monitoring, and discharge medication teaching.

Common supportive medications in detox settings may include agents for nausea, diarrhea, headache, insomnia, anxiety, and autonomic symptoms. Medication plans should be integrated with behavioral treatment and recovery support, not used in isolation.

In benzodiazepine poisoning, flumazenil has narrow use because it can precipitate withdrawal seizures in dependent patients or unsafe co-ingestion contexts. Use only in carefully selected scenarios under protocol guidance.

Clinical Judgment Application

Clinical Scenario

A client reports escalating nightly alcohol use and daytime sedative misuse with tremor, anxiety, and insomnia.

  • Recognize Cues: Escalating intake, role impairment, withdrawal signs, and dual-substance pattern.
  • Analyze Cues: Findings support probable SUD with active withdrawal risk.
  • Prioritize Hypotheses: Priority is safe withdrawal management and prevention of deterioration.
  • Generate Solutions: Start protocol-based monitoring, symptom treatment, and psychosocial engagement.
  • Take Action: Implement close observation, withdrawal scoring, and interprofessional referral planning.
  • Evaluate Outcomes: Monitor symptom reduction, improved participation, and linkage to continuing care.

Graph View